Stephen E. Langabeer

4.3k citations

104 papers · 2.7k indexed · 1 hit paper · h-index 20

Impact in

Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Genetics 70
- Myeloproliferative Neoplasms: Diagnosis and Treatment 48
- Chronic Lymphocytic Leukemia Research 22
Hematology 70
- Acute Myeloid Leukemia Research 42
- Chronic Myeloid Leukemia Treatments 38

Co-authors: David C. Linch (8 shared papers)Alan K. Burnett (11 shared papers)Rosemary E. Gale (3 shared papers)Marion E. Frew (4 shared papers)David Bowen (4 shared papers)Panagiotis Kottaridis (3 shared papers)Keith Wheatley (7 shared papers)Anthony H. Goldstone (5 shared papers)
Journals: British Journal of Haematology (14 papers)Blood (9 papers)Leukemia Research (2 papers)Pediatric Blood & Cancer (2 papers)Molecular Diagnosis & Therapy (2 papers)
Partner nations: Ireland United Kingdom United States

In The Last Decade

Stephen E. Langabeer

94 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials 2001 · 1.2k citations

Peers

Countries citing papers authored by Stephen E. Langabeer

Since Specialization

Citations

This map shows the geographic impact of Stephen E. Langabeer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Langabeer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Langabeer more than expected).

Fields of papers citing papers by Stephen E. Langabeer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Langabeer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Langabeer. The network helps show where Stephen E. Langabeer may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen E. Langabeer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen E. Langabeer Line = papers co-authored together Stephen E. Langabeer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 104 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood ·Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew, G Harrison, Stephen E. Langabeer, Andrea A. Belton, Helen M. Walker, Keith Wheatley, David Bowen, Alan K. Burnett, Anthony H. Goldstone, David C. Linch Hit paper breakdown →	2001	1178
2	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood ·Panagiotis Kottaridis, Rosemary E. Gale, Stephen E. Langabeer, Marion E. Frew, David Bowen, David C. Linch	2002	239
3	c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia British Journal of Haematology ·Mamdooh Gari, Anne Goodeve, Gill Wilson, Peter R. Winship, Stephen E. Langabeer, David C. Linch, Elisabeth Vandenberghe, Ian Peake, J. T. Reilly	1999	210
4	Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. PubMed ·David Grimwade, Patricia Gorman, Estelle Duprez, Kathy Howe, Stephen E. Langabeer, Fiona Oliver, Helen M. Walker, Dominic Culligan, Jonathan J. Waters, M. Pomfret, Anthony P. Goldstone, Alan K. Burnett, Paul S. Freemont, Denise Sheer, Ellen Solomon	1997	101
5	Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials British Journal of Haematology ·Stephen E. Langabeer, Hamish Walker, Joanne Rogers, Alan K. Burnett, Keith Wheatley, David Swirsky, Anthony H. Goldstone, D C Linch, (unknown)	1997	78
6	Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials British Journal of Haematology ·Stephen E. Langabeer, Helen M. Walker, R E Gale, Keith Wheatley, Alan K. Burnett, Anthony H. Goldstone, D C Linch	1997	74
7	Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia Leukemia ·Marc Tischkowitz, Neil V. Morgan, David Grimwade, Carey-Anne Eddy, Sarah E. Ball, Igor Vořechovský, Stephen E. Langabeer, Reinhard Stöger, S V Hodgson, Christopher G. Mathew	2004	61
8	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations British Journal of Haematology ·Anthony J. Bench, Helen White, Letizia Foroni, Anna L. Godfrey, Gareth Gerrard, Susanna Akiki, Abida Awan, Ian Carter, Andrea Goday‐Fernández, Stephen E. Langabeer, Tim Clench, Jordan J Clark, Paul Evans, David Grimwade, Anna Schuh, Mary Frances McMullin, Anthony R. Green, Claire Harrison, Nicholas C.P. Cross	2012	60
9	Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. PubMed ·David Grimwade, Kathy Howe, Stephen E. Langabeer, Alan K. Burnett, Anthony P. Goldstone, E. Solomon	1996	59
10	Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7 Genes Chromosomes and Cancer ·Stephen E. Langabeer, Rosemary E. Gale, Sara Rollinson, Gareth J. Morgan, David C. Linch	2002	47
11	Molecular diagnostics of myeloproliferative neoplasms European Journal Of Haematology ·Stephen E. Langabeer, Hajnalka Andrikovics, Julia Asp, Beatríz Bellosillo, Serge Carillo, Karl Haslam, Lasse Kjær, Éric Lippert, Olivier Mansier, Elisabeth Oppliger Leibundgut, Melanie J. Percy, Naomi Porret, Lars Palmqvist, Jiřı́ Schwarz, Mary Frances McMullin, Susanne Schnittger, Niels Pallisgaard, Sylvie Hermouet, (unknown)	2015	44
12	EVI1 expression in acute myeloid leukaemia British Journal of Haematology ·Stephen E. Langabeer, Joanne Rogers, G Harrison, Keith Wheatley, Helen M. Walker, Barbara J. Bain, Alan K. Burnett, Anthony H. Goldstone, David C. Linch, David Grimwade, On Behalf Of The Mrc Adult Leukaemia Working Party	2001	42
13	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML British Journal of Haematology ·Sarah Allford, David Grimwade, Stephen E. Langabeer, Estelle Duprez, Andrew J. Saurin, S Chatters, Helen M. Walker, Pamela Roberts, Joanne Rogers, Barbara J. Bain, Keith Patterson, Angela McKernan, Paul S. Freemont, Ellen Solomon, Alan Burnett, Anthony P. Goldstone, David C. Linch	1999	31
14	CYP1A12B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated withFLT3 internal tandem duplication Blood* ·David Bowen, Marion E. Frew, Sara Rollinson, Philippa L. Roddam, Ann Dring, Martyn T. Smith, Stephen E. Langabeer, Gareth J. Morgan	2003	31
15	Accessory cells do not contribute to G‐CSF or IL‐6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation British Journal of Haematology ·Michael Watts, H.M. Jones, Angela Sullivan, Stephen E. Langabeer, E. Jamieson, Adele K. Fielding, C. Williams, Ronald Berenson, Anthony H. Goldstone, David C. Linch	1995	30
16	Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia British Journal of Haematology ·Monica Pallis, Julie Turzanski, G Harrison, Keith Wheatley, Stephen E. Langabeer, Alan K. Burnett, Nigel H. Russell	1999	26
17	Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia Leukemia Research ·Stephen E. Langabeer, Fiona Quinn, David O’Brien, Anthony M. McElligott, Johanna Kelly, Paul Browne, Elisabeth Vandenberghe	2012	23
18	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML British Journal of Haematology ·Sarah Allford, David Grimwade, Stephen E. Langabeer, Estelle Duprez, Andrew J. Saurin, S Chatters, Helen M. Walker, Pamela Roberts, Joanne Rogers, Barbara J. Bain, Keith Patterson, Angela McKernan, Paul S. Freemont, Ellen Solomon, Alan K. Burnett, Anthony P. Goldstone, David C. Linch	1999	22
19	Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype International Journal of Laboratory Hematology ·Stephen E. Langabeer, David O’Brien, Stuart Liptrot, Catherine Flynn, Patrick Hayden, Eibhlin Conneally, Paul Browne, Elisabeth Vandenberghe	2012	21
20	Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia British Journal of Haematology ·David C. Rees, David Grimwade, Stephen E. Langabeer, Alan K. Burnett, Anthony P. Goldstone	1997	20

About Stephen E. Langabeer

Stephen E. Langabeer is a scholar working on Genetics, Hematology, Molecular Biology, Rheumatology and Public Health, Environmental and Occupational Health, having authored 104 papers that have together received 2.7k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (48 papers), Acute Myeloid Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (38 papers), Eosinophilic Disorders and Syndromes (35 papers), Chronic Lymphocytic Leukemia Research (22 papers), Kruppel-like factors research (18 papers), Acute Lymphoblastic Leukemia research (11 papers) and Retinoids in leukemia and cellular processes (11 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (959 citations), Public Health, Environmental and Occupational Health (584 citations), Molecular Biology (1.3k citations) and Rheumatology (214 citations). Stephen E. Langabeer has collaborated with scholars based in Ireland, United Kingdom and United States. Frequent co-authors include David C. Linch, Alan K. Burnett, Rosemary E. Gale, Marion E. Frew, David Bowen, Panagiotis Kottaridis, Keith Wheatley, Anthony H. Goldstone, Helen M. Walker and G Harrison. Their work appears in journals such as British Journal of Haematology, Blood, Leukemia Research, Pediatric Blood & Cancer and Molecular Diagnosis & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact